Stockscreener 앱 받기
19.35
0.62%
0.12
시간 외 거래:
19.75
0.40
+2.07%
Seres Therapeutics Inc 주식(MCRB)의 최신 뉴스
Custom strategy builders for tracking Seres Therapeutics Inc.Market Trend Review & Precise Buy Zone Tips - Newser
Statistical indicators supporting Seres Therapeutics Inc.’s strengthCEO Change & Stock Market Timing Techniques - Newser
Using fundamentals and technicals on Seres Therapeutics Inc.July 2025 Market Mood & Weekly Setup with High ROI Potential - Newser
Published on: 2025-08-19 05:10:31 - Newser
Seres Therapeutics Inc. stock momentum explainedJuly 2025 Sector Moves & Real-Time Chart Pattern Alerts - Newser
Earnings visualization tools for Seres Therapeutics Inc.Weekly Trend Report & Fast Entry High Yield Tips - Newser
How to integrate Seres Therapeutics Inc. into portfolio analysis toolsJuly 2025 Pullbacks & Capital Efficient Trade Techniques - Newser
How to track smart money flows in Seres Therapeutics Inc.Trade Analysis Summary & Scalable Portfolio Growth Ideas - Newser
Should you wait for a breakout in Seres Therapeutics Inc.2025 Analyst Calls & Trade Opportunity Analysis Reports - Newser
Is it time to cut losses on Seres Therapeutics Inc.Quarterly Profit Report & Risk Managed Investment Strategies - Newser
Historical volatility pattern of Seres Therapeutics Inc. visualizedBond Market & AI Forecasted Entry and Exit Points - Newser
Competitive Positioning of Seres Therapeutics Inc.: Is It Leading or LaggingTrade Analysis Summary & Short-Term Trading Alerts - Newser
Using data models to predict Seres Therapeutics Inc. stock movementEarnings Overview Report & Stock Market Timing Techniques - Newser
Risk adjusted return profile for Seres Therapeutics Inc. analyzedQuarterly Portfolio Report & Breakout Confirmation Trade Signals - Newser
Has Seres Therapeutics Inc. Stock Ever Crashed Historical Volatility ReviewJuly 2025 Big Picture & AI Enhanced Trading Alerts - Newser
Order flow analysis tools used on Seres Therapeutics Inc.2025 EndofYear Setup & Risk Adjusted Swing Trade Ideas - Newser
Seres (MCRB) Q2 Loss Narrows 34% - AOL.com
Seres Therapeutics Inc. Stock Performance After Earnings: Historical InsightsRisk Management & Weekly Watchlist for Consistent Profits - Newser
What moving averages say about Seres Therapeutics Inc.July 2025 Recap & Fast Entry Momentum Alerts - Newser
Published on: 2025-08-15 16:23:19 - Newser
Is Seres Therapeutics Inc. showing signs of accumulation2025 Market Sentiment & Risk Adjusted Buy and Sell Alerts - Newser
How does Seres Therapeutics Inc. score in quality rankingsEarnings Overview Summary & Fast Moving Stock Trade Plans - mustnews.co.kr
Institutional Tools Highlight Unusual Flow in Seres Therapeutics Inc.2025 Top Decliners & Accurate Entry/Exit Alerts - thegnnews.com
Should you avoid Seres Therapeutics Inc. stock right nowJuly 2025 Highlights & Long-Term Safe Investment Ideas - sundaytimes.kr
Why Seres Therapeutics Inc. stock attracts strong analyst attention2025 AllTime Highs & Daily Volume Surge Signals - Newser
Seres Therapeutics Inc. Bounces Off Moving Average SupportReal Trader Watchlist of Hot Stocks Released - metal.it
Seres Therapeutics Reports Q2 2025 Financial Results - The Globe and Mail
Seres Therapeutics’ Earnings Call: Progress Amid Challenges - TipRanks
Seres Therapeutics shares fall 1.90% after-hours following Q2 2025 earnings call. - AInvest
Promising Developments and Strategic Partnerships Drive Buy Rating for Seres Therapeutics - TipRanks
Seres Therapeutics outlines global Phase II SER-155 trial with 248-patient enrollment amid partnership talks - MSN
Seres Therapeutics: Q2 Earnings Snapshot - Connecticut Post
Seres Therapeutics: Unpacking Strategic Contradictions in Partnerships and FDA Engagements - AInvest
Seres Therapeutics, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:MCRB) - Seeking Alpha
Transcript : Seres Therapeutics, Inc., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Sana Biotechnology shares fall 14.12% after-hours following Seres Therapeutics' board changes and clinical advancement updates. - AInvest
Seres Therapeutics, Inc. SEC 10-Q Report - TradingView
Earnings call transcript: Seres Therapeutics reports larger-than-expected Q2 loss - Investing.com Canada
Seres Therapeutics quarterly loss per share $2.27 - MarketScreener
Seres Therapeutics August 2025 slides: SER-155 shows 77% infection reduction - Investing.com
Nxera debuts an obesity pipeline; BridgeBio battles Alynam for market share - Yahoo Finance
Seres Therapeutics: A High-Conviction Biotech Buy Amid Clinical and Strategic Momentum - AInvest
Seres Therapeutics Reports Second Quarter 2025 Financial Results - GuruFocus
Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates - Yahoo Finance
Seres Therapeutics Inc. Stock Analysis and ForecastAchieve consistent profits with proven methods - Jammu Links News
Is Seres Therapeutics Inc. a growth stock or a value stockRapid portfolio appreciation - Jammu Links News
0.95%
0.90%
자본화:
|
볼륨(24시간):